|12/21/17||Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit|
|Oral argument expected in second or third quarter of 2018
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) in the appeal of the PTAB’s decision in the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent.
The reply brief will beco... |
|11/29/17||Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018|
|COPENHAGEN, Denmark, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of further written submissions in the European Opposition Proceeding for the EP2801355 patent (“the ‘355 patent”) with the Opposition Division of the European Patent Office (“EPO”).
“We continue to vigorously defend our intellectual property and have filed strong argumentation to uphold our issued ‘355 patent,” said Dr. Claus Bo Svendsen, CEO of Forw... |
|11/27/17||Forward Pharma to Participate in Investor Conferences in December|
|COPENHAGEN, Denmark, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in two upcoming investor conferences in New York, NY.
Dr. Svendsen will host investor meetings at the Global Mizuho Investor Conference 2017 on Monday, December 4, 2017.
Additionally, Dr. Svendsen will host investor meetings at the Carnegie Nordic Healthcare Day on Tuesday, December 5, 2017 a... |
|11/22/17||Forward Pharma Announces Completion of Corporate Restructuring Plan|
|COPENHAGEN, Denmark, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward Pharma”) today announced the completion of its previously announced corporate restructuring plan (the “Restructuring”) substantially in the form set forth in Appendix D to the Settlement and License Agreement, dated January 17, 2017, by and among Forward Pharma, Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd. (collectively, “Biogen”) and certain other parties named therein (the “... |